172 related articles for article (PubMed ID: 22235098)
1. Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.
van de Ven SM; Elias SG; Chan CT; Miao Z; Cheng Z; De A; Gambhir SS
Clin Cancer Res; 2012 Feb; 18(4):1073-81. PubMed ID: 22235098
[TBL] [Abstract][Full Text] [Related]
2. In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.
Ardeshirpour Y; Chernomordik V; Hassan M; Zielinski R; Capala J; Gandjbakhche A
Clin Cancer Res; 2014 Jul; 20(13):3531-9. PubMed ID: 24671949
[TBL] [Abstract][Full Text] [Related]
3. In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging.
Hassan M; Chernomordik V; Zielinski R; Ardeshirpour Y; Capala J; Gandjbakhche A
Mol Imaging; 2012 Jun; 11(3):177-86. PubMed ID: 22554482
[TBL] [Abstract][Full Text] [Related]
4. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.
Niu G; Li Z; Cao Q; Chen X
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1510-9. PubMed ID: 19440708
[TBL] [Abstract][Full Text] [Related]
5. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.
Kramer-Marek G; Kiesewetter DO; Capala J
J Nucl Med; 2009 Jul; 50(7):1131-9. PubMed ID: 19525458
[TBL] [Abstract][Full Text] [Related]
6. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
9. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
Saitoh R; Nagayasu M; Shibahara N; Ono N; Suda A; Kato M; Ishigai M
Drug Metab Pharmacokinet; 2014; 29(2):185-91. PubMed ID: 24126359
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
[TBL] [Abstract][Full Text] [Related]
11. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
[TBL] [Abstract][Full Text] [Related]
12. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.
Wong C; Chen S
Cancer Res; 2009 Nov; 69(22):8670-7. PubMed ID: 19861537
[TBL] [Abstract][Full Text] [Related]
14. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
[TBL] [Abstract][Full Text] [Related]
15. 17-DMAG inhibits the multiplication of several Babesia species and Theileria equi on in vitro cultures, and Babesia microti in mice.
Guswanto A; Nugraha AB; Tuvshintulga B; Tayebwa DS; Rizk MA; Batiha GE; Gantuya S; Sivakumar T; Yokoyama N; Igarashi I
Int J Parasitol Drugs Drug Resist; 2018 Apr; 8(1):104-111. PubMed ID: 29499568
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
17. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
[TBL] [Abstract][Full Text] [Related]
18. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
Koll TT; Feis SS; Wright MH; Teniola MM; Richardson MM; Robles AI; Bradsher J; Capala J; Varticovski L
Mol Cancer Ther; 2008 Jul; 7(7):1985-92. PubMed ID: 18645008
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
